CheckMate 9LA Combination Effective in Advanced NSCLC Despite PD-L1 Expression, TMB Status
Leah LawrenceA higher tumor mutational burden (TMB) was associated with improved PFS and overall response rate for patients with advanced NSCLC treated with nivolumab plus ipilimumab plus chemotherapy compared with chemotherapy […] Read more
PACIFIC-R: Findings Reflect Clinical Reality of Consolidation Therapy in Stage III NSCLC
Leah LawrenceThe real-world assessment of durvalumab in patients with unresectable stage III NSCLC in the PACIFIC-R trial has highlighted important differences between this population and that of the original randomized […] Read more
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Con Side
Annemarie Fernandes Shepherd+more
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Pro Side
Kristin A. HigginsThe controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more
Symposium Chairs Reflect on Current Status, Next Steps for Lung Cancer Screening on a Global Scale
Joy CurzioIt has been documented and accepted that lung cancer screening saves lives by detecting disease in high-risk individuals at earlier stages, making the disease more treatable and leading to improved […] Read more
NCI Launches the Cancer Moonshot SM Biobank to Accelerate Research in Cancer Treatment
Helen M. Moore, PhDThe U.S. National Cancer Institute (NCI) Cancer Moonshot Biobank launched in September 2020, with the aim of accelerating cancer research by creating a resource of well-annotated, longitudinal cancer biospecimens from […] Read more
Consortium of Advocacy Groups, Professional Societies, and Industry Develops Consistent Language for Cancer Precision Medicine Testing
Jennifer ByrneIn recent years, precision medicine has begun to play an increasingly important role in cancer care. Advanced diagnostic testing, including testing for somatic mutations, non-genomic biomarkers, and germline mutations, is […] Read more
Voice from Asia: Combination of Immune Checkpoint Inhibitors With Chemotherapy for Advanced Non-squamous NSCLC
Weigang Xiu, MD, PhD+more
The immune checkpoint inhibitors (ICIs) monotherapy has resulted in significant improvements in PFS and OS in advanced NSCLC when compared with chemotherapy alone, and it has become the standard of […] Read more
ASCO and Ontario Health Publish Joint Guideline Update on Systemic Therapy for Stage IV NSCLC
Dr. Joan SchillerIn February 2021, the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) published a joint guideline update to the 2017 ASCO guidelines regarding systemic therapy for […] Read more
Immunotherapy Use in Patients With Lung Cancer and Comorbidities
Mitchell von Itzstein+more
Because nearly one-half of patients with advanced cancer are eligible for immune checkpoint inhibitor (ICI)–based treatment, these therapies are now in widespread clinical use.1 ICIs—whether as monotherapy, in checkpoint inhibitor […] Read more